Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

CDC significantly cuts estimate of omicron’s prevalence in US

The Centers for Disease Control and Prevention (CDC) significantly revised downward the estimate of the percentage of new COVID-19 infections in the U.S. caused by the omicron variant of the virus.

According to agency data, omicron accounted for about 59 percent of all U.S. infections as of Dec. 25. Previously, the CDC said the omicron variant comprised 73 percent of all cases for the week ending Dec. 18. But that number has now been revised to 22.5 percent of all cases.

The omicron variant is highly transmissible and spreading rapidly, resulting in surges of infections even among people who are vaccinated. However, people who are vaccinated, and especially those who have received booster shots, are well protected against severe disease from the variant, experts say, meaning it poses the greatest risk to the unvaccinated.

Source: The Hill

https://thehill.com/policy/healthcare/587506-cdc-lowers-estimate-of-omicron-prevalence-in-us

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!